Analyst Ratings For AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Today, Cantor Fitzgerald set its price target on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to $18.00 per share.
There are 7 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is Hold with a consensus target price of $22.4056 per share, a potential 23.65% upside.
Some recent analyst ratings include
- 8/3/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its Hold rating reiterated by Jefferies Financial Group with a $22.00 price target
- 6/15/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) gets downgraded to Neutral by Janney Montgomery Scott with a price target of $20.00
- 5/21/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has coverage initiated with a Market Perform rating and $24.65 price target
About AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Recent Trading Activity for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Shares of AMAG Pharmaceuticals, Inc. closed the previous trading session at 18,16 −0,60 3,20 % with shares trading hands.
